Smartphone apps as a source of cancer information: changing trends in health information-seeking behavior A Pandey, S Hasan, D Dubey, S Sarangi Journal of Cancer Education 28, 138-142, 2013 | 285 | 2013 |
YouTube as a source of information on kidney stone disease A Sood, S Sarangi, A Pandey, K Murugiah Urology 77 (3), 558-562, 2011 | 261 | 2011 |
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity P Sengupta, S Basu, S Soni, A Pandey, B Roy, MS Oh, KT Chin, ... Proceedings of the National Academy of Sciences 109 (28), 11294-11299, 2012 | 152 | 2012 |
Association of exclusive smokeless tobacco consumption with hypertension in an adult male rural population of India A Pandey, N Patni, S Sarangi, M Singh, K Sharma, AK Vellimana, S Patra Tobacco induced diseases 5, 1-5, 2009 | 79 | 2009 |
Principles of physics in surgery: the laws of mechanics and vectors physics for surgeons—part 2 A Srivastava, A Sood, PS Joy, S Mandal, R Panwar, S Ravichandran, ... Indian Journal of Surgery 72, 355-361, 2010 | 48 | 2010 |
Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy A Pandey, A Kulkarni, B Roy, A Goldman, S Sarangi, P Sengupta, ... Cancer research 74 (3), 675-685, 2014 | 37 | 2014 |
P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer S Sarangi, A Pandey, AL Papa, P Sengupta, J Kopparam, U Dadwal, ... Medical oncology 30, 1-6, 2013 | 33 | 2013 |
Effect of rotating acoustic stimulus on heart rate variability in healthy adults B Roy, R Choudhuri, A Pandey, S Bandopadhyay, S Sarangi, SK Ghatak The open neurology journal 6, 71, 2012 | 31 | 2012 |
Precision medicine and personalized breast cancer: combination pertuzumab therapy K Reynolds, S Sarangi, A Bardia, DS Dizon Pharmacogenomics and Personalized Medicine, 95-105, 2014 | 29 | 2014 |
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic AL Papa, A Sidiqui, SUA Balasubramanian, S Sarangi, M Luchette, ... Cellular Oncology 36, 449-457, 2013 | 29 | 2013 |
Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery A Pandey, S Sarangi, K Chien, P Sengupta, AL Papa, S Basu, ... Nanotechnology 25 (44), 445101, 2014 | 24 | 2014 |
The evolving role of circulating tumor cells in the personalized management of breast cancer: from enumeration to molecular characterization S Sarangi, K Mosalpuria, MJ Higgins, A Bardia Current breast cancer reports 6, 146-153, 2014 | 16 | 2014 |
Enhancing anti cancer activity of PI103, a dual PI3K/mTOR inhibitor, by designing a self assembled Nanoformulation B Roy, P Sengupta, S Soni, AL Papa, J Kopparam, S Sarangi, A Pandey, ... Cancer Research 72 (8_Supplement), 2892-2892, 2012 | | 2012 |
Abstract C187: Posttreatment with PI3-kinase inhibitor enhances the chemotherapeutic effect of cisplatin nanoparticles in breast cancer. A Pandey, B Roy, S Sarangi, P Sengupta, J Kopparam, S Basu, ... Molecular Cancer Therapeutics 10 (11_Supplement), C187-C187, 2011 | | 2011 |
Abstract B221: Clopidogrel augments cisplatin cytotoxicity by enhancing delivery and direct receptor mediated effects. A Pandey, S Sarangi, B Roy, P Sengupta, S Basu, J Kopparam, ... Molecular Cancer Therapeutics 10 (11_Supplement), B221-B221, 2011 | | 2011 |
Abstract B9: Smartphone applications as a source of cancer information A Pandey, S Sarangi, J Kopparam, B Roy Cancer Prevention Research 4 (10_Supplement), B9-B9, 2011 | | 2011 |
Mathematically modeling the sequential application of a cytotoxic nanoparticle and a PI3K-inhibitor enhances anti-tumor efficacy A Pandey, A Kulkarni, B Roy, A Goldman, S Sarangi, P Sengupta, ... | | |